Long-Term Psoriasis Treatment with Brodalumab: Is it Safe?

Long-term treatment of patients with psoriasis with brodalumab is both safe and effective, according to the results of a recent study.

While it has been established that brodalumab is effective for treatment of moderate-to-severe plaque psoriasis through 52 weeks, its safety and efficacy over a longer period is unknown.

The researchers conducted a randomized controlled trial of patients assigned to either brodalumab (n = 222) or placebo (n = 220). After 12 weeks, patients taking brodalumab who achieved static physician’s global assessment score of 0 or 1 (sPGA 0/1) were re-randomized to either brodalumab (n = 83) or to placebo (n = 84). Patients who had been receiving placebo also switched to treatment with brodalumab (n = 208).

Overall, treatment with brodalumab was associated with significant improvement in psoriasis area and severity index (PASI 75) and PASI 100 at week 120. After discontinuation of brodalumab, disease reoccurred after a mean of 74.7 days.

“These findings indicate that brodalumab is efficacious and safe for continuous long-term treatment of psoriasis and support potential for response after discontinuation and retreatment,” they concluded.

—Michael Potts

Reference:
Papp K, Menter A, Leonardi C, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomised phase 3 trial (AMAGINE-1) [published online April 14, 2020]. Br J Dermatol. doi: 10.1111/bjd.19132